arsenic trioxide nanoliposomes

Arsenic trioxide nanoliposomes are **experimental nanoliposomal formulations of arsenic trioxide** designed to improve delivery of this inorganic small-molecule antineoplastic agent to tumors. The encapsulated arsenic trioxide is intended to retain the known cytotoxic and pro-apoptotic activity of arsenic trioxide while using a liposomal nanocarrier to alter pharmacokinetics, reduce systemic toxicity, and enhance tumor accumulation; some reported research formulations also incorporate targeting ligands such as RGD peptides to promote uptake by integrin-expressing tumor cells. This is not a single branded commercial product but rather a **preclinical formulation concept** investigated by academic groups in oncology models including prostate cancer, pancreatic cancer, liver cancer, and glioma.

Other names

arsenic trioxide nanoliposomesnanoliposomal arsenic trioxideliposomal arsenic trioxidearsenic trioxide liposomes